Possible suppressive effects of baricitinib on serum IL-22 levels in atopic dermatitis

Baricitinib is an oral selective Janus kinase (JAK) 1 and 2 inhibitor used for moderate-to-severe atopic dermatitis (AD). Although its efficacy has been demonstrated in clinical trials [1,2], the immunological effects of baricitinib on AD are not yet fully understood. Interleukin (IL)-22 is a key molecule in several inflammatory skin diseases, including psoriasis and AD [3]. Here, 14 Japanese adult patients with moderate-to-severe AD who were treated with baricitinib at Gunma University Hospital were analyzed, and the relationship between serum IL-22 levels and disease activity of AD was presented.

Source: Journal of Dermatological Science - April 14, 2022 Category: Dermatology Authors: Akihiko Uchiyama, Chisako Fujiwara, Yuta Inoue, Mai Ishikawa, Sei-ichiro Motegi Tags: Letter to the Editor Source Type: research